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Homocysteine Augments Cytokine-Induced Chemokine
Expression in Human Vascular Smooth Muscle Cells:
Implications for Atherogenesis
Anjali Desai,1 Heather A. Lankford,1 and Jeffrey S. Warren1
Abstract—Hyperhomocysteinemia is an independent risk factor for atherosclerosis and atherothrom-
bosis. While in vitro studies have revealed a number of homocysteine-mediated alterations
in the thromboregulatory properties of endothelial cells, comparatively little is known about
homocysteine-modulated smooth muscle cell function. We observed that exposure of human aor-
tic smooth muscle cells to pathophysiologically relevant concentrations of homocysteine results
in concentration-dependent increases in cytokine-induced MCP-1 and IL-8 secretion. RNase
protection assays revealed that both MCP-1 and IL-8 mRNA concentrations are increased in
homocysteine-treated smooth muscle cells when compared to cells activated with cytokines alone.
Homocysteine treatment also increased cytosolic-to-nuclear translocation of the p65 and p50 sub-
units of the Rel/ NF-kB family of transcription factors but had no effect on AP-1 activation. Cumu-
latively, these data suggest that homocysteine may increase monocyte recruitment into developing
atherosclerotic lesions by upregulating MCP-1 and IL-8 expression in vascular smooth muscle cells.
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INTRODUCTION
Homocysteine, a sulfhydryl-containing amino acid pro-
duced as an intermediate in the methionine conservation
cycle, is a participant in both the single-carbon folate and
transulfuration pathways. Homozygous cystathionine-b-
synthase deficiency is very rare but is the most common
cause of marked hyperhomocysteinemia (up to 500 mM).
Patients who suffer with this disease which is marked by
developmental delay, osteoporosis, and ectopic lenses,
are prone to severe premature atherosclerotic vascu-
lar disease and vascular occlusion (1). Acquired and
heterozygous forms of hyperhomocysteinemia are rela-
tively common. These hyperhomocysteinemia states are
accompanied by an elevation in plasma methionine and
a reduction in plasma cysteine concentrations. Even rela-
tively modest hyperhomocysteinemia (15 mM–50 mM) is
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now recognized to be an independent risk factor for pre-
mature atherosclerotic coronary, cerebral, and peripheral
vascular disease (2). As many as 40% of patients who
suffer from complications of cerebrovascular or coronary
artery atherosclerosis are hyperhomocysteinemic.
During the past decade in vitro studies have
provided insight into potential mechanisms through
which homocysteine contributes to the development of
atherosclerosis and thrombosis. Most of these studies
have focused on homocysteine-mediated proatherothrom-
botic endothelial dysfunction. In contrast to the exten-
sive body of data which bear on mechanisms of
homocysteine-mediated endothelial dysfunction, com-
paratively little is known about potential mechanisms
of homocysteine-mediated vascular smooth muscle dys-
function. Homocysteine exposure has been reported to
increase collagen synthesis by rabbit aortic smooth mus-
cle cells and to stimulate vascular smooth muscle cell
proliferation (3). In turn, atherosclerotic lesions exhibit
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increased collagen content and proliferation of smooth
muscle cells (4). Recent studies indicate that homocys-
teine triggers the expression of inducible nitric oxide
synthase (iNOS) and concentration-dependent increases
in NO production by vascular smooth muscle cells (5).
It has been hypothesized that locally produced NO may
promote atherosclerosis by increasing local oxidative
stress.
The present study indicates that exposure of vascu-
lar smooth muscle cells to pathophysiologically relevant
concentrations of homocysteine results in augmentation
of cytokine-induced MCP-1 and IL-8 secretion and cor-
responding increases in MCP-1 and IL-8 mRNA con-
centrations. Electrophoretic mobility shift assay data also
indicate that homocysteine induces nuclear factor-kappa
B (NF-kB) (p50/ p65) cytosolic to nuclear translocation
but has no effect on activator protein-1 (AP-1).
METHODS
D,L-homocysteine and lipopolysaccharide (KPS)
from E. coli (serotype 0127:B8) were purchased from
Sigma (St. Louis, Missouri). Recombinant human tumor
necrosis factor-a(TNF-a), interferon-g (IFN-g) and
interleukin-1b (IL-1b) were obtained from R&D Sys-
tems (Minneapolis, Minnesota). Extraction of nuclear
protein, electrophoretic mobility shift assays and RNAse
protection assays were performed as previously described
(6)–(8). Human aorta vascular smooth muscle cells,
media, and media supplements were purchased from
Clonetics (Walkersville, Maryland). The cells were
grown and maintained as previously described (7).
Treatment of Smooth Muscle Cells for Enzyme
Immunoassay (EIA) Experiments. Smooth muscle cells
were exposed to the specified concentrations of homo-
cysteine (between 31mmol and 1 mmol) for 4 h. Subse-
quently, either TNF-a (1 ng/ ml or 10 ng/ ml, as indiated
or a mixture consisting of LPS (30 mg/ ml), IL-1b (50
ng/ ml) and IFN-g (50 ng/ ml) were added to the culture
media and the cells were incubated for an additional 8
h. Conditioned media were collected at the end of this
8 h incubation period and subjected to either MCP-1 or
IL-8 EIAs.
MCP-1 and IL-8 EIAs. Smooth muscle cells were
grown to confluence on 96-well flat bottom polystyrene
plates (Costar). Capture plates of MCP-1 or IL-8 were
prepared by coating sterile 96-well flat bottom ELISA
plates (Corning, Corning, New York) with anti-human
MCP-1 or anti-human IL-8 antibody, respectively (R&D
Systems, 50 ml/ well, 0.8 mg/ ml in PBS). The plates
were incubated at 48C overnight, washed with Wash
Buffer (0.05% Tween-20 in PBS, pH 7.4) and blocked
overnight at 48C with blocking buffer (0.05% Tween-
20, 1% BSA in PBS, pH 7.4) to reduce nonspecific
binding. Capture plates were stored at 48C until use.
One hundred ml aliquots of the conditioned cell media
and human recombinant MCP-1 or IL-8 standards (R&D
systems) were loaded into capture plates and incubated
at 48C overnight. Biotinylated anti-human MCP-1 or
anti-human IL-8 detection antibody (R&D Systems) was
added to each well (0.1 mg/ ml, 100 ml per well) and
plates were incubated at room temperature for 2 h. After
3 washes, streptavidin horseradish peroxidase was added
(Neutralite avidin, Southern Biotechnology Associates,
Birmingham, Alabama; 100 ml/ well, 1:4000 dilution)
and incubated for 30 min at room temperature. Wells
were washed to remove unbound conjugated peroxides
and then incubated with 100 ml/ well of peroxidase sub-
strate (ABTS, Boehringer Mannheim Biochemica, Ger-
many). After 0.5–4 h absorbance at 405 nm was mea-
sured using an automated microplate reader (ELx808,
Bio-Tek Instruments, Winooski, Vermont). Concentra-
tions of MCP-1 or IL-8 were calculated by 4 parameter
curve fitting regression analysis of rhMCP-1 or rhIL-8
standard curves using KC3 software (Bio-Tek Inc.).
Statistical Analysis. All values are expressed as the
means ± SE. Data were analyzed using Friedman two
way analysis of variance (ANOVA) with Bonferroni
comparison of means. Probability (P) values of < 0.05
were considered significant.
RESULTS
Homocysteine Augments Cytokine-Induced MCP-1
Expression. Exposure of smooth muscle cells to homo-
cysteine resulted in concentration-dependent increases
in MCP-1 secretion when the cells were subsequently
stimulated with either LPS, IFN-g and IL-1b (Figure
1) or TNF-a (Figure 2). Smooth muscle cells exposed
to medium alone secreted a small amount of MCP-
1 over the 12 h period of the experiment. Secretion
of MCP-1 was induced in smooth muscle cells pre-
treated with medium for 4 h and subsequently exposed
to LPS, IFN-g and IL-1b. When smooth muscle cells
were treated with varying concentrations of homocys-
teine (62.5 mM to 1 mM) prior to LPS, IFN-g and IL-
1b exposure, significant increases in MCP-1 concentra-
tions were detected. Maximum chemokine concentra-
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Fig. 1. Augmentation of cytokine-induced MCP-1 expression by
homocysteine. Smooth muscle cells were treated for 4 h with the indi-
cated concentrations of homocysteine, and subsequently a mixture con-
sisting of LPS, IFN-g and IL-1b was added. Conditioned media were
collected at 8 h following addition of stimuli and analyzed by MCP-1
EIA as described in “METHODS.” Asterisk* indicates significant dif-
ference from positive controls (MCP-1 concentrations in conditioned
media from cells that had been incubated in presence of LPS, IFN-g ,
and IL-1) as determined by Bonferroni comparison of means (27).
tions were measured at a concentration of 150 mM homo-
cysteine, when MCP-1 concentrations were increased
more than 2-fold over controls. Figures 2a and 2b are
representative of a series of similar EIA experiments
performed with TNF-a-treated smooth muscle cells (1
ng/ ml and 10 ng/ ml TNF-a respectively). Pretreatment
with homocysteine at concentrations ranging from 62.5
mM to 1 mM resulted in significantly elevated MCP-1
concentrations (compared to smooth muscle cells pre-
treated only with medium prior to TNF-a activation)
when cells were subsequently activated with 1 ng/ ml
TNF-a. Pretreatment with homocysteine at concentra-
tions ranging from 125 mM to 1 mM resulted in sig-
nificantly elevated MCP-1 concentrations (compared to
smooth muscle cells pretreated only with medium prior
to TNF-a activation) when cells were subsequently acti-
vated with 10 ng/ ml TNF-a. For both concentrations
of TNF-a tested, MCP-1 expression was maximally
induced with 250 mM homocysteine.
Homocysteine Augments Cytokine-Induced IL-8
Expression. Analogous results for IL-8 were observed
in aortic smooth muscle cells exposed to homocysteine
Fig. 2. Augmentation of TNF-a-induced MCP-1 expression by homo-
cysteine. Smooth muscle cells were treated for 4 h with varying doses
of homocysteine, and subsequently TNF-a at either 1 ng/ ml (Figure
2A) or 10 ng/ ml (Figure 2B) was added. Conditioned media were col-
lected at 8 h following addition of stimuli and analyzed by MCP-1
EIA as described in “METHODS.” Asterisk* denotes significant dif-
ference from positive controls (MCP-1 concentrations in conditioned
media from cells that had been incubated in presence of TNF-a) as
determined by Bonferroni comparison of means (27).
followed by LPS, IFN-g and IL-1b (Figure 3). Smooth
muscle cells treated with LPS, IL-1b and IFN-g secreted
approximately twice the amount of IL-8 compared to
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Fig. 3. Augmentation of cytokine-induced IL-8 expression by homo-
cysteine. Smooth muscle cells that had been pretreated for 4 h with the
indicated concentrations of homocysteine (31.25 mM to 1 mM) were
incubated in the presence of a mixture of LPS, IL-1b and IFN-g for
8 h. The conditioned media were collected and analyzed by IL-8 EIA
as described in “METHODS.” Asterisk∗ denotes significant difference
from positive controls (IL-8 concentrations in conditioned media from
cells that had been incubated in presence of LPS, IFN-g , and IL-1) as
determined by Bonferroni comparison of meams (27).
media-treated controls. Pretreatment with 250 mM of
homocysteine resulted in maximum IL-8 concentrations
that were increased by 170% when compared to cells
pretreated only with prior to activation by LPS, IL-1b
and IFN-g.
Homocysteine Increases Cytokine-Induced NK-kB
Translocation. Martin et al. (9) recently reported that
MCP-1 gene expression in endothelial cells in response
to cytokine stimulation depends on the cooperative inter-
action of the redox-sensitive transcription factors NF-k
B and AP-1. NF-kB is a ubiquitous factor present in the
cytosol of most quiescent cells in a complex with an
inhibitor, IkB-a (10, 11). When the cell is appropriately
stimulated, IkB-a is degraded, thus releasing NF-kB and
allowing it to translocate to the nucleus where it can bind
to cis-acting kB-sites in the promoters and enhancers
of genes, thereby modulating their transcription. Nuclear
extracts prepared from smooth muscle cells exposed to
250 mM homocysteine or medium alone for 4 h followed
by TNF-a exposure for 45 min and 90 min, respectively,
were subjected to electrophoretic mobility shift assays
with a kB consensus oligonucleotide. As seen in Fig-
ure 4, there were significant increases in binding to the
Fig. 4. Electrophoretic mobility shift analysis of nuclear extracts
derived from smooth muscle cells. Cells were exposed to 250 mM
homocysteine or medium followed by 1. TNF-a for 45 min (lanes 1
and 2) 2. TNF-a for 90 min (lanes 3 and 4) 3. medium for 90 min
(lanes 5 and 6). Nuclear extracts were incubated in presence of a radi-
olabeled double-stranded NF-kB consensus oligonucleotide probe for
30 min at room temperature and samples were run on a nondenaturing
4% polyacrylamide gel.
NF-kB recognition sequence in smooth muscle cells pre-
exposed to homocysteine (lanes 2 and 4) as compared
to smooth muscle cells exposed to medium alone (lanes
1 and 3) prior to cytokine activation. Competition with
a 50-fold excess of unlabeled (cold) NF-kB abrogated
the gel shift whereas addition of an unlabeled irrelevant
oligonucleotide probe (Oct1) did not affect NF-kB detec-
tion (data not shown).
Characterization of NF-kB/ Rel Family Members
Activated by Homocysteine and Cytokines. In order to
delineate which members of the NF-kB/ Rel family of
transcription factors are activated in smooth muscle cells
upon exposure to homocysteine and cytokines, super-
shift assays utilizing antibodies for the p65, p50, p52,
c-Rel and Rel B subunits were performed. Representa-
tive results from these EMSA analyses can be seen in
Figure 5. Lanes 1–6 depict supershift assays performed
with nuclear extracts from smooth muscle cells incu-
bated for 4 h in presence of medium followed by a
45 min exposure to TNF-a. In lane 7, nuclear extract
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Fig. 5. Supershift analyses of nuclear extracts derived from cytokine-
activated smooth muscle cells. Cells were subjected to a 4 h exposure
to either medium (lanes 1–6) or homocysteine (250 mM) followed by
a 45 min incubation in presence of TNF-a. Nuclear extracts were pre-
pared as described in “METHODS.” Extracts were preincubated with
antibodies to either p65 (lanes 2 and 8), p50 (lanes 3 and 9), c-Rel
(lanes 4 and 10), Rel B (lanes 5 and 11) or p52 (lanes 6 and 12) for
30 min prior to addition of the NF-kB oligonucleotide probe. Samples
were run on a nondenaturing 4% polyacrylamide gel. Lanes 1 and 7
depict binding activities of nuclear extracts without preincubation with
supershift antibodies.
from smooth muscle cells that had been subjected to a
4 h incubation in presence of homocysteine followed
by 45 min of TNF-a was subjected to electrophore-
sis without prior incubation with supershift antibod-
ies. Supershifts occurred when nuclear extract-oligonu-
cleotide probe complexes were incubated with either
anti-p65 (lane 8) or anti-p50 (lane 9) antibodies. Incu-
bation with antibodies to either c-Rel (lane 10), Rel B
(lane 11), or p52 (lane 12), failed to induce supershifts
of the DNA-protein complexes.
Homocysteine does not Affect AP-1 Activation. AP-
1 is a redox-sensitive transcription factor composed of
homo- or heterodimers of members of Fos and Jun fam-
ilies which bind to the TPA (12-O-tetradecanoylphorbol-
13-acetate) responsive element (TRE) motif to mediate
gene transcription (12). It has been shown to be indis-
pensable for maximum cytokine induction of MCP-1
in endothelial cells (9). Figure 6 depicts a representa-
tive EMSA experiment with an AP-1 consensus oligonu-
cleotide. No significant differences in AP-1 activation
Fig. 6. AP-1 gel shift analysis of nuclear extracts derived from TNF-
a-activated smooth muscle cells. Cells were exposed to 250 mM homo-
cysteine or medium followed by 1. TNF-a for 45 min (lanes 1 and 2)
2. TNF-a for 90 min (lanes 3 and 4) 3. medium for 90 min (lanes 5
and 6). Nuclear extracts were incubated in presence of a radiolabeled
double-stranded AP-1 consensus oligonucleotide probe for 30 min at
room temperature and samples were run on a nondenaturing 4% poly-
acrylamide gel.
were observed in nuclear extracts from homocysteine-
treated smooth muscle cells (Figure 6, lanes 2 and 4)
when compared to cells that were only incubated in pres-
ence of medium prior to cytokine stimulation (Figure 6,
lanes 1 and 3).
Homocysteine Treatment Augmnts MCP-1 and IL-
8 mRNA Concentrations. In order to determine whether
increased levels of IL-8 and MCP-1 mRNAs were
present in homocysteine pretreated smooth muscle cells
we utilized a multi-probe RNase protection assay. Fig-
ures 7 and 8 depict time courses for the appearances
of MCP-1 and IL-8 mRNAs in smooth muscle cells
incubated in the presence of homocysteine (250 mM) or
medium followed by a mixture of LPS, IL-1b and IFN-g
(Figure 7) or TNF-a (Figure 8), respectively. Low con-
centrations of IL-8 and MCP-1 mRNAs were present
in unstimulated smooth muslce cells (Figure 7, lane 7;
Figure 8, lane 7). At 2, 4, and 6 h following expo-
sure to LPS, IL-1b and IFN-g, both IL-8 and MCP-
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Fig. 7. MCP-1 and IL-8 mRNAs in cytokine-activated smooth muscle
cells. RNase protection assay was utilized in order to detect specific
transcripts for both chemokines and for the “housekeeping genes, L32
and GAPDH, as controls. Cells were exposed to 250 mM homocysteine
or medium for 4 h followed by a mixture of LPS, IL-1b, and IFN-g
for 2 h (lanes 1 and 2), 4 h (lanes 3 and 4), or 6 h (lanes 5 and 6).
Lanes 7 and 8 represent mRNAs from smooth muscle cells that had
been incubated in presence of medium alone or 250 mM homocysteine
for 10 h, respectively.
1 transcripts were significantly upregulated in homo-
cysteine pretreated cells (Figure 7, lanes 2, 4, 6) as
compared to controls (smooth muscle cells exposed to
medium prior to LPS, IL-1b and IFN-g stimulation; Fig-
ure 7, lanes 1, 3, 5). Maximum concentrations of both
IL-8 and MCP-1 mRNAs were detected following a 4-h
exposure of smooth muscle cells to homocysteine fol-
lowed by a 4-h incubation in presence of LPS, IL-1b
and IFN-g (Figure 7, lane 4). As can be seen in Fig-
ure 8, homocysteine pretreatment for 4 h followed by
TNF-a exposure for 2, 4, and 6 h respectively (lanes 2, 4
and 6), resulted in significantly elevated IL-8 and MCP-
1 mRNA concentrations when compared to media-pre-
treated cells (lanes 1, 3, and 5).
DISCUSSION
The recruitment, proliferation, and activation of
multiple cell types (i.e. monocytes, T-lymphocytes,
smooth muscle cells, endothelial cells) within lesions are
critical features of the chronic inflammatory and fibro-
Fig. 8. MCP-1 and IL-8 mRNAs in TNF-a-activated smooth muscle
cells. RNase protection assay was utilized in order to detect specific
transcripts for both chemokines and for the “housekeeping” genes, L32
and GAPDH, as controls. Cells were exposed to 250 mM homocysteine
or medium for 4 h followed by TNF-a for 2 h (lanes 1 and 2), 4 h (lanes
3 and 4), or 6 h (lanes 5 and 6). Lanes 7 and 8 represent mRNAs from
smooth muscle cells that had been incubated in presence of medium
alone or 250 mM homocysteine for 10 h, respectively.
proliferative responses central to atherosclerosis (13),
(14). MCP-1, a member of the C-C or beta subfamily
of chemokines is abundant in macrophage-rich areas of
atherosclerotic lesions and is believed to be atherogenic,
in part by promoting the firm adhesion of leukocytes
to endothelium that facilitates chemotactic transmigra-
tion (14). Aiello et al. (15) recently reported that MCP-1
expression by leukocytes, predominantly macrophages,
hastens the progression of atherosclerosis in apolipo-
protein E-deficient mice by increasing both macrophage
numbers and oxidized lipid accumulation.
The C-X-C chemokine IL-8 has also recently been
recognized to promote atherogenesis by virtue of its
ability to trigger the firm adhesion of monocytes to
vascular endothelium (16). Interleukin-8 is secreted by
macrophages, endothelial and smooth muscle cells and,
like homocysteine, is a potent mitogenic stimulus for
smooth muscle cells (17). Interleukin-8 has angiogenic
properties and is chemotactic for T-lymphocytes which
are present in atherosclerotic lesions (18). Rus et al.
(19) measured protein levels and gene expression of IL-
8 in the human arterial atherosclerotic wall and observed
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that IL-8 protein concentrations are increased signifi-
cantly in fibrous plaques compared to normal arterial
media and intima. In addition, IL-8 transcripts are also
expressed in the walls of human arteriosclerotic ves-
sels. Wang et al. (20) reported that THP-1 macrophages
incubated with acetylated LDL exhibit increased IL-
8 mRNA concentrations. Interleukin-8 induction has
also been observed in fresh human monocyte-derived
macrophages cells exposed to acetylated LDL. Immuno-
histochemical and in situ hybridization studies using
human coronary atheromas have revealed IL-8 mRNA
in macrophage-rich areas. Macrophages from atheroscle-
rotic plaques exhibit an enhaced capacity to produce
IL-8 compared to normal blood monocytes (21). More-
over, intimal macrophages express the growth-related
oncogene (GRO) and IL-8 receptor mlL-8RH/ CXR2 in
advanced murine and human atherosclerotic lesions (22).
Elevated plasma homocysteine concentrations were
first linked to atherosclerosis three decades ago (23)
but the mechanisms by which homocysteine exerts its
atherothrombotic action remain controversial. Accumu-
lating evidence suggests that hyperhomocysteinemia,
through the oxidation of homocysteine, leads to endothe-
lial injury and dysfunction mediated by reactive oxygen
intermediates (ROIs) such as superoxide anion, hydro-
gen peroxide (H2O2), and hydroxyl radical (24). These
ROIs in turn have been identified as potent activators of
the redox-sensitive transcription factor NF-kB in a vari-
ety of cell lines (10). NF-kB is critical for the expression
of many genes involved in atherogenesis including those
encoding pathophysiologically relevant cytokines (IL-1,
TNF-a), chemokines (IL-8, MCP-1, GRO a), growth
factors (granulocyte macrophage colony stimulating fac-
tor (GM-CSF), and adhesion molecules (vascular cell
adhesion molecule 1 (VCAM-1) (25), (26).
Most published studies regarding the effect of
hyperhomocysteinemia on smooth muscle cells have
foucsed on the mitogenic properties of homocysteine.
We observed that pathophysiologically relevant con-
centrations of homocysteine increase cytokine-mediated
MCP-1 and IL-8 expression by smooth muscle cells
at both the protein and mRNA level. To our knowl-
edge this is the first report addressing the effects of
homocysteine on chemokine expression by smooth mus-
cle cells. Welch et al. (5) recently reported that expo-
sure of vascular smooth musle cells to homocysteine
prior to cytokine stimulation leads to an increase in
NF-kB-mediated Nos2 transcription. Catalase and super-
oxide dismutase reduced cytokine activation of NF-kB
after homocysteine exposure by 35% and 40%, respec-
tively, suggesting that ROIs generated during oxidation
of homocysteine facilitate cytokine-dependent activation
of NF-kB (5). In addition, a significant increase in hydro-
gen peroxide (H2O2) formation was detected in condi-
tioned media from homocysteine-treated smooth mus-
cle cells. Cumulatively, the studies reported by Welch
et al. (5) and our data suggest that exposure of smooth
muscle cells to pathophysiologically relevant concentra-
tions of homocysteine results in increased cytosolic-to-
nuclear translocation of NF-kB which in turn results in
the increased expression of several relevant inflamma-
tory mediators.
Upregulation of MCP-1 expression by homo-
cysteine may accelerate atherogenesis by facilitat-
ing increased recruitment of monocytes into sites of
atheroma development. Activated lesional monocyte-
macrophages promote the progression of atherosclerosis
by scavenging and oxidizing LDL, thus producing proin-
flammatory oxidized lipids and by expressing a variety
of growth factors, cytokines, complement proteins and
proteases. MCP-1 modulates not only monocyte (and
T lymphocyte) recruitment but also monocyte activa-
tion, including the expression of some complement pro-
teins, IL-1, and the procoagulant tissue factor, thereby
potentially contributing to thrombotic events associated
with atherosclerosis (14). The mitogenic properties of
both IL-8 and homocysteine may facilitate an autocrine
pathway in smooth cells: IL-8 elaboration by activated
smooth muscle cells may result in increased numbers
of smooth muscle cells which may in turn secrete even
greater concentrations of IL-8. Since IL-8 can induce
the firm adhesion of rolling monocytes onto monolayers
expressing E-selectin (16) and is chemotactic for T-cells,
upregulation of IL-8 expression by homocysteine would
likely also result in increased recruitment of monocytes
and T-hymphocytes to sites of atherosclerotic lesions.
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